Neratinib: First Global Approval

Overview

Journal Drugs

Specialty Pharmacology

Date 2017 Sep 9

PMID 28884417

Citations 52

Authors

Emma D Deeks

Affiliations

Soon will be listed here.

Abstract

Neratinib (Nerlynx™) is an oral, irreversible inhibitor of the human epidermal growth factor receptors HER1 (EGFR), HER2 and HER4. The drug originally arose from research by Wyeth (now Pfizer) and is now being developed by Puma Biotechnology primarily for the treatment of HER2-positive (HER+) breast cancer. Neratinib is approved in the USA for the extended adjuvant treatment of patients with HER2+ early-stage breast cancer who have been previously treated with a trastuzumab-based adjuvant regimen, and is in the preregistration phase for this indication in the EU. Neratinib, as monotherapy and/or combination therapy, is also in phase 3 development for metastatic breast cancer and in phase 1/2 development for advanced breast cancer and other solid tumours, including non-small cell lung cancer, colorectal cancer and glioblastoma. This article summarizes the milestones in the development of neratinib leading to this first approval for breast cancer.

Citing Articles

Small molecule-mediated inhibition of the oxidoreductase ERO1A restrains aggressive breast cancer by impairing VEGF and PD-L1 in the tumor microenvironment.

Varone E, Retini M, Cherubini A, Chernorudskiy A, Marrazza A, Guidarelli A Cell Death Dis. 2025; 16(1):105.

PMID: 39962052 PMC: 11833095. DOI: 10.1038/s41419-025-07426-1.

Phase I trial of the combination of the pan-ErbB inhibitor neratinib and mTOR inhibitor everolimus in advanced cancer patients with ErbB family gene alterations.

Piha-Paul S, Tseng C, Tran H, Naing A, Dumbrava E, Karp D ESMO Open. 2025; 10(2):104136.

PMID: 39908697 PMC: 11847258. DOI: 10.1016/j.esmoop.2025.104136.

Unlocking the potential: unveiling tyrphostins with Michael-reactive cyanoacrylate motif as promising inhibitors of human 5-lipoxygenase.

Molitor M, Menge A, Mandel S, George S, Muller S, Knapp S Pflugers Arch. 2024; 476(12):1913-1928.

PMID: 39347835 PMC: 11582101. DOI: 10.1007/s00424-024-03019-7.

Neratinib safety evaluation: real-world adverse event analysis from the FAERS database.

Fan Y, Wu T, Xu P, Yang C, An J, Zhang H Front Pharmacol. 2024; 15:1425171.

PMID: 39346561 PMC: 11427278. DOI: 10.3389/fphar.2024.1425171.

Nanotechnology in the development of small and large molecule tyrosine kinase inhibitors and immunotherapy for the treatment of HER2-positive breast cancer.

Ejigah V, Mandala B, Akala E J Cancer Metastasis Res. 2024; 4(2):6-22.

PMID: 38966076 PMC: 11223443.

References

Martin M, Bonneterre J, Geyer Jr C, Ito Y, Ro J, Lang I . A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. Eur J Cancer. 2013; 49(18):3763-72. DOI: 10.1016/j.ejca.2013.07.142. View

Burstein H, Sun Y, Dirix L, Jiang Z, Paridaens R, Tan A . Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol. 2010; 28(8):1301-7. DOI: 10.1200/JCO.2009.25.8707. View

Sequist L, Besse B, Lynch T, Miller V, Wong K, Gitlitz B . Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010; 28(18):3076-83. DOI: 10.1200/JCO.2009.27.9414. View

Tai W, Mahato R, Cheng K . The role of HER2 in cancer therapy and targeted drug delivery. J Control Release. 2010; 146(3):264-75. PMC: 2918695. DOI: 10.1016/j.jconrel.2010.04.009. View

Keyvanjah K, DiPrimeo D, Li A, Obaidi M, Swearingen D, Wong A . Pharmacokinetics of neratinib during coadministration with lansoprazole in healthy subjects. Br J Clin Pharmacol. 2016; 83(3):554-561. PMC: 5306479. DOI: 10.1111/bcp.13132. View

Lopez S, Cocco E, Black J, Bellone S, Bonazzoli E, Predolini F . Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo. Mol Cancer Ther. 2015; 14(11):2519-26. PMC: 4636465. DOI: 10.1158/1535-7163.MCT-15-0383. View

Park J, Liu M, Yee D, Yau C, J van t Veer L, Fraser Symmans W . Adaptive Randomization of Neratinib in Early Breast Cancer. N Engl J Med. 2016; 375(1):11-22. PMC: 5259558. DOI: 10.1056/NEJMoa1513750. View

Gandhi L, Bahleda R, Tolaney S, Kwak E, Cleary J, Pandya S . Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors. J Clin Oncol. 2013; 32(2):68-75. DOI: 10.1200/JCO.2012.47.2787. View

Rabindran S, Discafani C, Rosfjord E, Baxter M, Floyd M, Golas J . Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res. 2004; 64(11):3958-65. DOI: 10.1158/0008-5472.CAN-03-2868. View

10.

Canonici A, Gijsen M, Mullooly M, Bennett R, Bouguern N, Pedersen K . Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer. Oncotarget. 2013; 4(10):1592-605. PMC: 3858548. DOI: 10.18632/oncotarget.1148. View

11.

Iqbal N, Iqbal N . Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Mol Biol Int. 2014; 2014:852748. PMC: 4170925. DOI: 10.1155/2014/852748. View

12.

Breslin S, Lowry M, ODriscoll L . Neratinib resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4. Br J Cancer. 2017; 116(5):620-625. PMC: 5344284. DOI: 10.1038/bjc.2016.445. View

13.

Shimamura T, Ji H, Minami Y, Thomas R, Lowell A, Shah K . Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. Cancer Res. 2006; 66(13):6487-91. DOI: 10.1158/0008-5472.CAN-06-0971. View

14.

Awada A, Dirix L, Manso Sanchez L, Xu B, Luu T, Dieras V . Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy. Ann Oncol. 2012; 24(1):109-16. DOI: 10.1093/annonc/mds284. View

15.

Ma C, Bose R, Gao F, Freedman R, Telli M, Kimmick G . Neratinib Efficacy and Circulating Tumor DNA Detection of Mutations in Nonamplified Metastatic Breast Cancer. Clin Cancer Res. 2017; 23(19):5687-5695. PMC: 6746403. DOI: 10.1158/1078-0432.CCR-17-0900. View

16.

Ito Y, Suenaga M, Hatake K, Takahashi S, Yokoyama M, Onozawa Y . Safety, efficacy and pharmacokinetics of neratinib (HKI-272) in Japanese patients with advanced solid tumors: a Phase 1 dose-escalation study. Jpn J Clin Oncol. 2012; 42(4):278-86. DOI: 10.1093/jjco/hys012. View

17.

Montemurro F, Di Cosimo S, Arpino G . Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications. Ann Oncol. 2013; 24(11):2715-24. DOI: 10.1093/annonc/mdt287. View

18.

Menderes G, Bonazzoli E, Bellone S, Black J, Lopez S, Pettinella F . Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo. Med Oncol. 2017; 34(5):91. PMC: 5896014. DOI: 10.1007/s12032-017-0956-8. View

19.

Jankowitz R, Abraham J, Tan A, Limentani S, Tierno M, Adamson L . Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2‑positive breast cancer: an NSABP Foundation Research Program phase I study. Cancer Chemother Pharmacol. 2013; 72(6):1205-12. DOI: 10.1007/s00280-013-2262-2. View

20.

Chow L, Xu B, Gupta S, Freyman A, Zhao Y, Abbas R . Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer. Br J Cancer. 2013; 108(10):1985-93. PMC: 3670493. DOI: 10.1038/bjc.2013.178. View